NYSE: BMYBristol Myers Squibb Co Stock
$49.23-0.13 (-0.26%)
Updated Apr 17, 2025
BMY Price
$49.23
Fair Value Price
N/A
Market Cap
$99.90B
52 Week Low
$39.35
52 Week High
$63.33
P/E
-11.16x
P/B
6.12x
P/S
2.38x
PEG
N/A
Dividend Yield
3.7%
Revenue
$48.30B
Earnings
-$8.95B
Gross Margin
71.1%
Operating Margin
-17.38%
Profit Margin
-18.5%
Debt to Equity
4.67
Operating Cash Flow
$15B
Beta
0.34
Next Earnings
Apr 25, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BMY Overview
Bristol-Myers Squibb Company is one of the world's largest pharmaceutical companies. It manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders. Unlike some of its more diversified peers, Bristol-Myers has exited several nonpharmaceutical businesses to focus on branded specialty drugs. The company was founded in 1887 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BMY's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
BMY
Ranked#4 of 18
Ranked#4 of 18
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $104.54 | A | |
| $78.00 | A | |
| $110.86 | A |
Be the first to know about important BMY news, forecast changes, insider trades & much more!
BMY News
Overview
Due Diligence Score
–
Industry Average (38)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BMY scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BMY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BMY is poor value based on its book value relative to its share price (6.12x), compared to the US Drug Manufacturers - General industry average (6.01x)
P/B vs Industry Valuation
BMY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more BMY due diligence checks available for Premium users.
Valuation
BMY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.16x
Industry
52.36x
Market
27.98x
BMY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.12x
Industry
6.01x
BMY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BMY's financial health
Profit margin
Revenue
$12.3B
Net Income
$72.0M
Profit Margin
0.6%
BMY's Earnings (EBIT) of -$8.39B... subscribe to Premium to read more.
Interest Coverage Financials
BMY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$92.6B
Liabilities
$76.2B
Debt to equity
4.67
BMY's short-term assets ($29.78B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BMY's long-term liabilities ($52.44B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BMY's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BMY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$4.4B
Investing
-$196.0M
Financing
-$1.6B
BMY's operating cash flow ($15.19B)... subscribe to Premium to read more.
Debt Coverage Financials
BMY vs General Drug Manufacturer Stocks
Bristol Myers Squibb Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.